Preliminary Study on β3-Adrenoreceptor as Predictor Marker of Relapse in Ewing Sarcoma Patients

Ewing sarcoma (EWS) is a paediatric aggressive malignant tumour of bones and soft tissues. Multidisciplinary chemotherapies, surgical resection, and radiation represent the only strategies counteracting the disease, however spreading and relapse of disease still remain a clinical issue. Circulating tumour cells (CTCs) are an important feature of EWS but the prognostic significance has not been, yet, clarified. CTCs have been found both in patients with localized disease and in those who recur or metastasize. The identification of markers that can detect recurrences and metastasis remains an important challenge for research. Unfortunately, even most of patients with localized cancer relapsed and the reason has not yet been fully understood. In this clinical study on EWS patients, we evaluated the expression of CD99 antigen and beta-3 adrenergic receptor (β3-AR) on CTCs and bioptic derived cells by flow cytometry. The preliminary data revealed a higher β3-AR expression on cells derived from metastatic or relapsed patients, suggesting a role for the β3-AR as a possible predictive maker of disease recurrence in both patients with metastatic and localized disease.

Download Full-text

Clinicopathologic correlations of cutaneous neuroendocrine Merkel cell carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.1988.6.12.1863 ◽

1988 ◽

Vol 6 (12) ◽

pp. 1863-1873 ◽

Cited By ~ 80

Author(s):

S Pilotti ◽

F Rilke ◽

C Bartoli ◽

A Grisotti

Keyword(s):

Cell Carcinoma ◽

Merkel Cell Carcinoma ◽

Soft Tissues ◽

Prognostic Significance ◽

Lower Limbs ◽

Second Primary ◽

Merkel Cell ◽

Second Primary Malignancy ◽

Regional Metastases ◽

Localized Disease

A study of 50 consecutive cases (22 men, 28 women; age range, 39 to 84 years; mean age, 65 years) of cutaneous neuroendocrine Merkel cell carcinoma (CNC), 39 of whom had a mean follow-up of 34 months, revealed that the prognostic significance of the histopathologic subtyping in trabecular, solid, and diffuse variants of CNC was not as important as the pathologic postsurgical staging in localized, regional, and extraregional disease. The overall mortality was 23.5%. None of the 19 patients with localized disease died of CNC, while 11% of the 24 patients with regional disease and all seven patients with extraregional disease at presentation died of CNC. A second primary malignancy was found to be associated with the CNC in 15% of the cases. The clinical course in patients with localized disease was favorable in spite of the high number of local recurrences. Also, the presence of regional metastases was not related to an unfavorable prognosis. In 68% of the cases the disease involved the lower limbs or girdle. In ten cases the overt exophytic presentation of primary CNC was replaced by the presence of tumor masses infiltrating the inguinal soft tissues with or without nodal involvement.

Download Full-text

Outcomes of Adult Ewing Sarcoma Treated with Multimodality Therapy: A Single-Institute Experience

South Asian Journal of Cancer ◽

10.1055/s-0041-1723108 ◽

2020 ◽

Vol 09 (04) ◽

pp. 191-194

Author(s):

Ravi Chandran ◽

Siva Prasad Kuruva ◽

Rachana Chennamaneni ◽

Stalin Bala ◽

Meher Lakshmi Konatam ◽

...

Keyword(s):

Metastatic Disease ◽

Ewing Sarcoma ◽

Univariate Analysis ◽

Lactate Dehydrogenase Level ◽

Serum Lactate ◽

Normal Serum ◽

Multimodality Therapy ◽

Serum Lactate Dehydrogenase ◽

Common Symptom ◽

Localized Disease

Abstract Introduction Ewing sarcoma (ES) is more common in children and relatively rare in adults. Adult ES has poor prognosis than children. Treatment approaches for adults have been extrapolated from pediatric experience. Data on adult ES are very few because of its rarity in adults. The present study was done to analyze the clinical profile and outcome of adult ES. Aims The aim was to study the clinical and pathological treatment and outcomes in adult ES. Subjects and Methods Between 2010 and 2017, a total of 73 ES patients with age more than 18 years were retrospectively analyzed. Survival analysis was done by plotting Kaplan–Meier curves. Results A total of 73 patients were diagnosed with ES during 2010 to 2017. Among them, 43 (58.9%) had localized disease with a median age of 24.5 years. Males were 44 (60.3%) and females were 29 (39.7). Pain (75.3%) was the most common symptom at presentation. Nine patients had incomplete details and were excluded from the analysis. Among 21 (28.8%) patients, the lung (61.9%) was the most common site of metastasis followed by the bone, bone marrow, and brain. The median number of chemotherapy cycles in the localized disease was 14 (range 1–17), and in metastatic disease, it was 4 (range 1–7). Univariate analysis was done with respect to age (< 25 vs. ≥25), gender, elevated or normal serum lactate dehydrogenase level, tumor size (< 8 cm versus ≥8 cm), site (axial versus extremity), and neoadjuvant chemotherapy (NACT) given or not. NACT had a significant impact on overall survival (OS) and the rest had no effect. At a median follow-up of 40 months, the 3-year OS in localized disease was 87.4%. In metastatic disease, the median OS was 13 months with 3-year OS of 26%. Conclusions Outcomes with multimodality therapy in adult ES patients with localized disease are comparable to that of a pediatric cohort. However, metastatic disease has poor survival.

Download Full-text

Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial

Journal of Clinical Oncology ◽

10.1200/jco.2013.54.4833 ◽

2014 ◽

Vol 32 (23) ◽

pp. 2440-2448 ◽

Cited By ~ 72

Author(s):

Marie-Cécile Le Deley ◽

Michael Paulussen ◽

Ian Lewis ◽

Bernadette Brennan ◽

Andreas Ranft ◽

...

Keyword(s):

Ewing Sarcoma ◽

Local Treatment ◽

Consolidation Treatment ◽

Intention To Treat ◽

Response To Chemotherapy ◽

Radiotherapy Alone ◽

Localized Disease ◽

Gonadal Toxicity ◽

Major Treatment ◽

Standard Risk

Purpose Relative efficacy and toxicity of cyclophosphamide compared with ifosfamide are debatable. The Euro-EWING99-R1 trial asked whether cyclophosphamide may replace ifosfamide in combination with vincristine and dactinomycin (vincristine, dactinomycin, and cyclophosphamide [VAC] v vincristine, dactinomycin, and ifosfamide [VAI]) after an intensive induction chemotherapy containing vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in standard-risk localized disease (NCT00020566). Methods Standard-risk Ewing sarcomas were localized tumors with either a good histologic response to chemotherapy (< 10% cells) or small tumors (< 200 mL) resected at diagnosis or receiving radiotherapy alone as local treatment. Patients entered the trial after six VIDE+1 VAI courses. Allocated treatment was either 7 VAC courses with 1.5 g/m2 of cyclophosphamide or seven VAI-courses with 6 g/m2 ifosfamide. The limit of noninferiority was set at −8.5% for the 3-year event-free survival rate (EFS), equivalent to 1.43 in terms of the hazard ratio of event (HRevent). Results This large international trial recruited 856 patients between February 2000 and March 2010 (n = 431 receiving VAC and n = 425 receiving VAI). With a median follow-up of 5.9 years, the 3-year EFSs were 75.4% and 78.2%, respectively, the 3-year EFS difference was −2.8% (91.4% CI, −7.8 to 2.2%), the HRevent was 1.12 (91.4% CI, 0.89 to 1.41), and the HRdeath was 1.09 (91.4% CI, 0.84 to 1.42; intention-to-treat). The HRevent was 1.22 (91.4% CI, 0.96 to 1.54) on the per-protocol population. Major treatment modifications were significantly less frequent in the VAC arm (< 1%) than in the VAI arm (7%), mainly resulting from toxicity. Patients experienced more frequent thrombocytopenia in the VAC arm (45% v 35%) but fewer grade 2 to 4 acute tubular toxicities (16% v 31%). Conclusion Cyclophosphamide may be able to replace ifosfamide in consolidation treatment of standard-risk Ewing sarcoma. However, some uncertainty surrounding the noninferiority of VAC compared with VAI remains at this stage. The ongoing comparative evaluation of long-term renal and gonadal toxicity is crucial to decisions regarding future patients.

Download Full-text

Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of Clinical Oncology ◽

10.1200/jco.2008.19.5933 ◽

2009 ◽

Vol 27 (22) ◽

pp. 3705-3711 ◽

Cited By ~ 43

Author(s):

David A. Rodeberg ◽

Julie A. Stoner ◽

Andrea Hayes-Jordan ◽

Simon C. Kao ◽

Suzanne L. Wolden ◽

...

Keyword(s):

Alternative Therapy ◽

Prognostic Significance ◽

Complete Response ◽

Disease Recurrence ◽

Radiographic Measurement ◽

Clinical Group ◽

Group Iii ◽

Best Response ◽

Pathology Reports ◽

The Impact

Purpose Some patients with rhabdomyosarcoma (RMS) achieve less than a complete response (CR) despite receiving all planned therapy. We assessed the impact of best response at the completion of all therapy on patient outcome. Patients and Methods We studied 419 clinical group III participants who completed all protocol therapy without developing progressive disease for Intergroup Rhabdomyosarcoma Study (IRS) IV. Response (complete resolution [CR], partial response [PR; ≥ 50% decrease], or no response [NR; < 50% decrease and < 25% increase]) was determined by radiographic measurement and categorized by the best response. Results At the end of therapy, 341 participants (81%) achieved a best response of CR and 78 (19%) had a best response of PR/NR. Five-year failure-free survival was similar for participants achieving CR (80%) and PR/NR (78%). After adjustment for age, nodal status, primary site, and histology, there was no significant indication of lower risk of failure (hazard ratio [HR], 0.77; 95% CI, 0.46 to 1.27; P = .3) nor death (HR, 0.63; 95% CI, 0.36 to 1.09; P = .1) for CR versus PR/NR participants. Seventeen participants with a best response of PR/NR had surgical procedures; eight (50%) of 16 with available pathology reports had residual viable tumor and only three achieved a complete resection. Resection of residual masses was not associated with improved outcome. Conclusion CR status at the end of protocol therapy in clinical group III participants was not associated with a reduction of disease recurrence and death. Aggressive alternative therapy may not be warranted for RMS patients with a residual mass at the end of planned therapy.

Download Full-text

Machine Learning-Based Prediction Model for Papillary Thyroid Carcinoma Recurrence

10.21203/rs.3.rs-113105/v1 ◽

2020 ◽

Author(s):

Young Min Park ◽

Byung-Joo Lee

Keyword(s):

Machine Learning ◽

Prediction Model ◽

Tumor Size ◽

Large Scale ◽

Prediction Models ◽

Prognostic Significance ◽

Disease Recurrence ◽

Machine Learning Techniques ◽

Papillary Thyroid ◽

Recurrence Prediction

Abstract Background: This study analyzed the prognostic significance of nodal factors, including the number of metastatic LNs and LNR, in patients with PTC, and attempted to construct a disease recurrence prediction model using machine learning techniques.Methods: We retrospectively analyzed clinico-pathologic data from 1040 patients diagnosed with papillary thyroid cancer between 2003 and 2009. Results: We analyzed clinico-pathologic factors related to recurrence through logistic regression analysis. Among the factors that we included, only sex and tumor size were significantly correlated with disease recurrence. Parameters such as age, sex, tumor size, tumor multiplicity, ETE, ENE, pT, pN, ipsilateral central LN metastasis, contralateral central LNs metastasis, number of metastatic LNs, and LNR were input for construction of a machine learning prediction model. The performance of five machine learning models related to recurrence prediction was compared based on accuracy. The Decision Tree model showed the best accuracy at 95%, and the lightGBM and stacking model together showed 93% accuracy. Conclusions: We confirmed that all machine learning prediction models showed an accuracy of 90% or more for predicting disease recurrence in PTC. Large-scale multicenter clinical studies should be performed to improve the performance of our prediction models and verify their clinical effectiveness.

Download Full-text

Is histological remission of ulcerative colitis achievable?

Terapevticheskii arkhiv ◽

10.26442/00403660.2021.08.200981 ◽

2021 ◽

Vol 93 (8) ◽

pp. 975-981

Author(s):

Oleg V. Knyazev ◽

Anna V. Kagramanova ◽

Sergei G. Khomeriki ◽

Asfold I. Parfenov

Keyword(s):

Ulcerative Colitis ◽

Clinical Remission ◽

Therapeutic Efficacy ◽

Disease Recurrence ◽

Mucosal Healing ◽

Colon Mucosa ◽

Normal Colon ◽

Laboratory Markers ◽

Important Challenge ◽

Histological Remission

Current conception of deep remission in patients with ulcerative colitis (UC) consists of clinical remission, endoscopic mucosal healing and normalization of laboratory markers. Histological remission should not be used as a primary end point for therapeutic efficacy, but instead should be considered as a marker of deep remission. The main goal of UC treatment should be focused on endoscopic healing of colon mucosa, decrease of inflammation activity, prolonged remission, absence of disease recurrence, and also histologic remission. Nevertheless, the term histologic remission has not yet been fully validated and no histologic indexes have been standardized. We need single unified definition for remission, based on multicentral studies analysis. One of important challenge is restoration of normal colon mucosal and results of multiple studies showed contradictory tests for assessing histologic remission, thus remaining an issue for further discussion.

Download Full-text

Prognostic significance of beta-2 adrenergic receptor in oral squamous cell carcinoma

Cancer Biomarkers ◽

10.3233/cbm-2012-0228 ◽

2012 ◽

Vol 10 (1) ◽

pp. 51-59 ◽

Cited By ~ 13

Author(s):

Diego Mauricio Bravo-Calderón ◽

Denise Tostes Oliveira ◽

Aparecido Nilceu Marana ◽

Suely Nonogaki ◽

André Lopes Carvalho ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Oral Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Adrenergic Receptor ◽

Prognostic Significance ◽

Beta 2

Download Full-text

Colon Cancer

10.2310/cgso.16028 ◽

2018 ◽

Author(s):

Richard S Hoehn ◽

Felipe Quezada-Diaz ◽

Jesse J Smith

Keyword(s):

Colon Cancer ◽

Adjuvant Chemotherapy ◽

Surgical Resection ◽

Distant Metastases ◽

Disease Recurrence ◽

The United States ◽

Oncologic Outcomes ◽

Perioperative Outcomes ◽

Increased Risk ◽

Localized Disease

Colon cancer is a leading cause of cancer-related death in the United States and worldwide. Routine screening has led to early diagnosis and improved survival for many patients but is still greatly underused. Complete surgical resection provides the best opportunity for cure of localized disease and requires removal of a defined segment of colon along with its lymphovascular pedicle, including a minimum of 12 lymph nodes. Minimally invasive approaches have been shown to provide better perioperative outcomes and patient recovery, with oncologic outcomes equivalent to those of traditional open surgery. Patients with lymph node metastases are at an increased risk of distant metastases and disease recurrence. Survival for these patients has improved in the recent years with the advent of oxaliplatin-based adjuvant chemotherapy. In addition, surgical resection is increasingly being used to control and sometimes cure distant metastases. In this chapter, we review the current strategies for diagnosing and managing colon cancer. This review contains 1 video, 5 figures, 4 tables and 48 references Key Words: adjuvant chemotherapy, anastomosis, colectomy, colon cancer, neoadjuvant chemotherapy, surgery, survival, laparoscopic, robotic

Download Full-text

Prognostic significance of β2-adrenergic receptor expression in patients with surgically resected colorectal cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-020-01645-6 ◽

2020 ◽

Vol 25 (6) ◽

pp. 1137-1144 ◽

Cited By ~ 1

Author(s):

Hiroomi Ogawa ◽

Kyoichi Kaira ◽

Yoko Motegi ◽

Takehiko Yokobori ◽

Takahiro Takada ◽

...

Keyword(s):

Colorectal Cancer ◽

Adrenergic Receptor ◽

Prognostic Significance ◽

Receptor Expression ◽

Β2 Adrenergic Receptor

Download Full-text

Prognostic significance of LINC00460 overexpression in solid tumours: a meta-analysis

Postgraduate Medical Journal ◽

10.1136/postgradmedj-2019-137172 ◽

2020 ◽

Vol 96 (1135) ◽

pp. 286-295

Author(s):

Chen Dai ◽

Yan Zhang ◽

Hao Ni ◽

Yuting Kuang ◽

Zhihua Xu

Keyword(s):

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Malignant Tumour ◽

Positive Lymph Node ◽

Cochrane Library ◽

Cancer Type ◽

Malignant Tumours ◽

Node Metastasis ◽

Solid Malignant Tumour

The prognostic value of long intergenic non-protein coding RNA 460 (LINC00460) overexpression in human solid malignant tumours remains unclear. Therefore, we conducted the meta-analysis to systematically review and assess the evidence for the correlation between LINC00460 overexpression and clinicopathological features and overall survival (OS) of patients with solid malignant tumour. An electronic search of PubMed, EMBASE, Web of Science, CNKI, Cochrane Library, Chinese Biological Medical Literature database and WanFang database was applied to select eligible articles. Pooled ORs or HRs with their 95% CIs were calculated to estimate the effects. 9 eligible studies with a total of 935 patients were enrolled in this meta-analysis. The results revealed that high LINC00460 expression was associated with positive lymph node metastasis (positive vs negative: OR=2.97, 95% CI 1.74 to 5.05, p=0.812), advanced tumour-node-metastasis stage (III+IV vs I+II: OR=2.82, 95% CI 1.64 to 4.85, p=0.193) and poorer differentiation (high vs low: OR=0.60, 95% CI 0.36 to 0.99, p=0.569). Additionally, the overexpression of LINC00460 could predict a poorer OS (HR=1.57, 95% CI 1.39 to 1.77) and the shorter disease-free survival (HR=2.32, 95% CI 1.25 to 4.31). Furthermore, according to subgroup analysis and meta-regression results, the heterogeneity of current meta-analysis may be attributed to the differences of cancer type and follow-up months. High expression of LINC00460 could predict poor prognosis in patients with solid malignant tumour. LINC00460 may serve as potential prognostic biomarker for clinical outcomes in various human solid malignant tumours.

Download Full-text